Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vicor Technologies has reported positive clinical study results of proprietary PD2i Cardiac Analyzer, a patented device utilized in risk stratification of patients for sudden cardiac death.
Subscribe to our email newsletter
The study has enrolled 37 patients (30 of which completed the study) and achieved a sensitivity of 100% and a specificity of 81%.
David Fater, Vicor’s president and CEO, said: “We continue to demonstrate through our clinical efforts that our proprietary PD2i Analyzer has the ability to accurately risk stratify patients into those who require implantable cardioverter defibrillation (ICD) intervention and those who do not.”